Niagen Bioscience Q2 net sales $29.8M, net income $1.0M; launches pharmaceutical program targeting rare diseases

Niagen Bioscience, Inc.

Net sales $29.8M ($24.2M Tru Niagen); gross margin 64.8%; net income $1.0M ($0.01 EPS); adjusted EBITDA $3.0M.
Launched Niagen Plus telehealth platform with at-home injection kit; received LegitScript certification for advertising.
Introduced NB4168 for rare genetic diseases targeting Ataxia-Telangiectasia; received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations.
Appointed Abhijit Kale as Senior Director of Global External Research to lead pharmaceutical program.
2026 outlook: e-commerce growth 10-15% YoY; ingredient business expected lower; expects increased operating expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.